The regulatory shift targets companies operating in sectors identified in China's current five-year economic plan, including quantum technology, nuclear fusion, and brain-computer interfaces. By leveraging the STAR Market’s fifth listing standard, these firms—many of which remain pre-profit—can now access public funding to sustain the heavy research and development costs required for their long-term growth.

Wu Qing, chairman of the China Securities Regulatory Commission, stated that the move is a direct response to the integration of AI into production and daily life. The commission intends to guide more long-term "patient" capital into equity investments to bolster local innovation. This policy adjustment mirrors an ongoing effort to redirect domestic resources toward strategic technologies, including hydrogen energy, robotics, and biomedical engineering. Several prominent homegrown players, such as memory-chip giant ChangXin Memory Technologies and robot manufacturer Unitree Robotics, are expected to utilize these streamlined paths to the domestic market in the near future.